Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 8 |
List of Tables | 8 | 1 |
List of Figures | 9 | 1 |
Introduction | 10 | 1 |
Global Markets Direct Report Coverage | 10 | 1 |
Dry (Atrophic) Macular Degeneration Overview | 11 | 1 |
Therapeutics Development | 12 | 2 |
Pipeline Products for Dry (Atrophic) Macular Degeneration Overview | 12 | 1 |
Pipeline Products for Dry (Atrophic) Macular Degeneration Comparative Analysis | 13 | 1 |
Dry (Atrophic) Macular Degeneration Therapeutics under Development by Companies | 14 | 2 |
Dry (Atrophic) Macular Degeneration Therapeutics under Investigation by Universities/Institutes | 16 | 1 |
Dry (Atrophic) Macular Degeneration Pipeline Products Glance | 17 | 4 |
Late Stage Products | 17 | 1 |
Clinical Stage Products | 18 | 1 |
Early Stage Products | 19 | 1 |
Unknown Stage Products | 20 | 1 |
Dry (Atrophic) Macular Degeneration Products under Development by Companies | 21 | 2 |
Dry (Atrophic) Macular Degeneration Products under Investigation by Universities/Institutes | 23 | 1 |
Dry (Atrophic) Macular Degeneration Companies Involved in Therapeutics Development | 24 | 27 |
Aciont Inc. | 24 | 1 |
Alimera Sciences, Inc. | 25 | 1 |
Allergan Plc | 26 | 1 |
Apellis Pharmaceuticals Inc | 27 | 1 |
Astellas Pharma Inc. | 28 | 1 |
Benitec Biopharma Limited | 29 | 1 |
Biophytis SAS | 30 | 1 |
Catalyst Biosciences, Inc. | 31 | 1 |
Cell Cure Neurosciences, Ltd. | 32 | 1 |
Charlesson LLC. | 33 | 1 |
Foamix Pharmaceuticals Ltd. | 34 | 1 |
Genentech Inc | 35 | 1 |
GenSight Biologics S.A. | 36 | 1 |
GlaxoSmithKline Plc | 37 | 1 |
Icon Bioscience, Inc. | 38 | 1 |
Inception Sciences, Inc. | 39 | 1 |
Johnson &Johnson | 40 | 1 |
Kodiak Sciences Inc. | 41 | 1 |
MacuCLEAR Inc | 42 | 1 |
MeiraGTx Limited | 43 | 1 |
Novartis AG | 44 | 1 |
Ophthotech Corp. | 45 | 1 |
Orphagen Pharmaceuticals, Inc. | 46 | 1 |
pSivida Corp. | 47 | 1 |
Samumed LLC | 48 | 1 |
Sucampo Pharmaceuticals, Inc. | 49 | 1 |
Sun Pharma Advanced Research Co Ltd | 50 | 1 |
Dry (Atrophic) Macular Degeneration Therapeutics Assessment | 51 | 9 |
Assessment by Monotherapy Products | 51 | 1 |
Assessment by Target | 52 | 2 |
Assessment by Mechanism of Action | 54 | 2 |
Assessment by Route of Administration | 56 | 2 |
Assessment by Molecule Type | 58 | 2 |
Drug Profiles | 60 | 61 |
A-005 Drug Profile | 60 | 1 |
APL-2 Drug Profile | 61 | 2 |
avacincaptad pegol sodium Drug Profile | 63 | 2 |
BBAMD-231 Drug Profile | 65 | 1 |
BIO-201 Drug Profile | 66 | 1 |
brimonidine tartrate implant Drug Profile | 67 | 2 |
CLG-561 Drug Profile | 69 | 1 |
CLT-005 Drug Profile | 70 | 1 |
CNTO-2476 Drug Profile | 71 | 1 |
Drug for Age Related Macular Degeneration Drug Profile | 72 | 1 |
EG-30 Drug Profile | 73 | 1 |
FMX-103 Drug Profile | 74 | 2 |
Gene Therapy for Dry Macular Degeneration and Retinitis Pigmentosa Drug Profile | 76 | 1 |
Gene Therapy for Ocular Diseases Drug Profile | 77 | 1 |
GS-030 Drug Profile | 78 | 1 |
GSK-933776 Drug Profile | 79 | 1 |
ICR-14967 Drug Profile | 80 | 1 |
KSI-401 Drug Profile | 81 | 1 |
lampalizumab Drug Profile | 82 | 2 |
MA09-hRPE Drug Profile | 84 | 10 |
MC-1101 Drug Profile | 94 | 2 |
methotrexate Drug Profile | 96 | 1 |
OCU-100 Drug Profile | 97 | 1 |
ONL-1204 Drug Profile | 98 | 1 |
OpRegen Drug Profile | 99 | 3 |
OpRegen Plus Drug Profile | 102 | 1 |
RC-1 Alpha Drug Profile | 103 | 1 |
Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration Drug Profile | 104 | 1 |
RST-001 Drug Profile | 105 | 2 |
Small Molecule for Dry AMD and Wet AMD Drug Profile | 107 | 1 |
Small Molecules for AMD Drug Profile | 108 | 1 |
Small Molecules for Dry Age-Related Macular Degeneration Drug Profile | 109 | 1 |
Small Molecules for Dry AMD Drug Profile | 110 | 1 |
Small Molecules for Dry and Wet Age Related Macular Degeneration Drug Profile | 111 | 1 |
Small Molecules to Inhibit NADPH Oxidase for Dry Macular Degeneration Drug Profile | 112 | 1 |
Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration Drug Profile | 113 | 2 |
tesidolumab Drug Profile | 115 | 2 |
unoprostone isopropyl Drug Profile | 117 | 3 |
VM-100 Drug Profile | 120 | 1 |
Dry (Atrophic) Macular Degeneration Dormant Projects | 121 | 3 |
Dry (Atrophic) Macular Degeneration Discontinued Products | 124 | 1 |
Dry (Atrophic) Macular Degeneration Product Development Milestones | 125 | 10 |
Featured News &Press Releases | 125 | 1 |
Aug 30, 2016: RetroSense Therapeutics Granted Patent on Proprietary Method for Restoring Vision using Optogenetics | 125 | 1 |
May 05, 2016: RetroSense Therapeutics to Highlight Contributions to Gene Therapy Research in Upcoming Conferences | 125 | 1 |
Apr 12, 2016: BIOPHYTIS to Present Pre-Clinical Data on BIO 201 at Upcoming Scientific Conference | 126 | 1 |
Nov 17, 2015: Biophytis establishes New subsidiary to accelerate clinical development of Maculia | 126 | 1 |
Oct 01, 2013: Roche to present data on Lampalizumab at investor event | 127 | 1 |
Aug 27, 2013: Roche s lampalizumab phase II data shows benefit in patients with the advanced form of dry age-related macular degeneration | 127 | 1 |
Jul 17, 2013: ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials | 128 | 1 |
May 16, 2013: ACT Confirms Clinical Trial Participant Shows Improvement In Vision Following Treatment With Human Embryonic Stem Cells | 129 | 1 |
Apr 15, 2013: ACT Treats First Patient with Better Vision in Clinical Trial for Stargardt s Macular Dystrophy | 129 | 1 |
Apr 01, 2013: ACT Initiates Treatment Of Higher-dosage Cohort In Clinical Trials For Dry Age-related Macular Degeneration And Stargardt's Macular Dystrophy | 130 | 1 |
Mar 14, 2013: Advanced Cell Technology Receives DSMB Approval To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials Using hESC-derived RPE Cells | 131 | 1 |
Feb 15, 2013: OgenX Therapeutics Announces Presentation Of RAVEN-1 Trial Final Results At Snowmass Ophthalmology Conference | 132 | 1 |
Jan 08, 2013: Advanced Cell Technology Achieves Clinical Milestone | 132 | 1 |
Nov 28, 2012: ACT Completes Higher-Dosage Cohort In Both US Clinical Trials Using Retinal Pigment Epithelial Cells | 133 | 1 |
Aug 02, 2012: ACT Announces First Dry Age-Related Macular Degeneration Patient Treated With Higher Dosage Of Embryonic Stem Cell-Derived RPE Cells | 134 | 1 |
Appendix | 135 | 2 |
Methodology | 135 | 1 |
Coverage | 135 | 1 |
Secondary Research | 135 | 1 |
Primary Research | 135 | 1 |
Expert Panel Validation | 135 | 1 |
Contact Us | 135 | 1 |
Disclaimer | 136 | 1 |